Corvus Pharmaceuticals, Inc. Uncategorized Contracts & Agreements

14 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Description of Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Corvus Pharmaceuticals, Inc.
Biotechnology
2025
Sub-Sublease, by and between NewLimit, Inc. and Corvus Pharmaceuticals, Inc., dated as of October 22, 2024
Corvus Pharmaceuticals, Inc.
Biotechnology
2024
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Corvus Pharmaceuticals, Inc.
Biotechnology
2024
Open Market Sale Agreement, dated November 1, 2021, by and between Corvus Pharmaceuticals, Inc. and Jefferies LLC
Corvus Pharmaceuticals, Inc.
Biotechnology
NY
2022
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Corvus Pharmaceuticals, Inc.
Biotechnology
2021
Phase I/IB Combination Study Agreement, dated October 5, 2015, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
Corvus Pharmaceuticals, Inc.
Biotechnology
DE
2020
Amendment No. 1 to the Phase 1b/II Combination Study Agreement dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
Corvus Pharmaceuticals, Inc.
Biotechnology
2020
Amendment No. 2 to the Phase I/IB Combination Study Agreement, dated August 1, 2019, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
Corvus Pharmaceuticals, Inc.
Biotechnology
2020
Amendment No. 1 to the Phase I/IB Combination Study Agreement, dated December 20, 2017, by and between Corvus Pharmaceuticals, Inc. and Genentech, Inc
Corvus Pharmaceuticals, Inc.
Biotechnology
2020
Description of Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
Corvus Pharmaceuticals, Inc.
Biotechnology
2020
Offer Letter, dated as of January 7, 2019 by and between Corvus Pharmaceuticals, Inc. and Mehrdad Mobasher
Corvus Pharmaceuticals, Inc.
Biotechnology
2019
Offer Letter, dated as of November 22, 2017 by and between Corvus Pharmaceuticals, Inc. and Daniel Hunt
Corvus Pharmaceuticals, Inc.
Biotechnology
CA
2018
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with...
Corvus Pharmaceuticals, Inc.
Biotechnology
DE
2017
PHASE I/IB COMBINATION STUDY AGREEMENT BY AND BETWEEN GENENTECH, INC. AND CORVUS PHARMACEUTICALS, INC.
Corvus Pharmaceuticals, Inc.
Biotechnology
DE
2016